Decoding Nighttime Cough: What It Means for Cystic Fibrosis and Ciliary Dyskinesia
"A new study uncovers how nighttime cough patterns differ in patients with cystic fibrosis and ciliary dyskinesia, offering potential clues for better diagnosis and treatment."
Coughing, a common reflex, plays a vital role in clearing our airways and protecting our lungs. But what happens when cough becomes a persistent nighttime companion? For individuals with chronic respiratory conditions such as cystic fibrosis (CF) and primary ciliary dyskinesia (PCD), nighttime cough can be more than just an annoyance; it can be a significant indicator of disease progression and overall health. Cystic fibrosis is a genetic disorder that causes the body to produce thick and sticky mucus that can clog the lungs and obstruct the pancreas. Primary ciliary dyskinesia (PCD) is a rare genetic condition that affects the function of cilia, tiny hair-like structures that line the airways and help to clear mucus.
While doctors often rely on patient reports and standard lung function tests, these methods have limitations. Patient accounts of cough can be subjective and may not always align with objective measurements. Traditional lung function tests might not be suitable for all age groups, and questionnaires can introduce biases. This is why researchers are increasingly interested in finding reliable and easily assessable markers—surrogates—that reflect the true severity of these conditions. Cough frequency, measured objectively, has emerged as a potential candidate.
Recognizing the need for more precise methods, a team of researchers set out to explore the nuances of nighttime cough in individuals with CF and PCD. Their study, a prospective observational analysis, aimed to determine if cough patterns are related to disease severity and if there are notable differences between CF and PCD patients. By using advanced sound monitoring technology, the researchers hoped to uncover valuable insights that could lead to improved diagnostic and therapeutic strategies.
CF Burden and Cough
A cough-monitoring paper reports that excessive gastro-oesophageal reflux is very frequent in people with cystic fibrosis (CF) and may lead to recurrent aspiration and irritation of airway sensory nerves, described as cough hypersensitivity. A national indicator report describes CF as a genetic disease affecting breathing and digestion. It estimates that about 40,000 children and adults in the United States have CF.
A Community’s Milestones
The Cystic Fibrosis Foundation says it was founded in 1955. It describes working alongside the CF community since then to transform the disease in a single generation. The Foundation presents its milestones as part of the pursuit of a cure and calls CF’s story one of medicine’s most amazing.
Unlocking the Secrets of Nighttime Cough: What the Study Revealed
In this study, researchers used the LEOSound® Monitor, a sophisticated microphone-based system, to track and analyze cough patterns in three groups: healthy subjects (HS), patients with cystic fibrosis (CF), and patients with primary ciliary dyskinesia (PCD). Each group consisted of 25 participants, and their coughs were monitored over two consecutive nights in their home environments. The goal was to count and compare the number of coughs and cough epochs (a series of coughs occurring close together) during the night.
- Cough Frequency: Healthy subjects coughed very little at night, with a median of 0.0 coughs per hour. In contrast, CF patients had a median of 1.3 to 2.3 coughs per hour, while PCD patients had a median of 0.2 to 0.5 coughs per hour.
- Group Differences: CF and PCD patients coughed significantly more than healthy subjects. Additionally, CF patients coughed more than PCD patients.
- Key Risk Factor: A multivariable analysis identified forced expiratory volume in one second (FEV1) as an independent risk factor for increased cough frequency. FEV1 is a measure of how much air a person can exhale in one second, and lower values indicate poorer lung function.
- Reliability: The reliability of repeated measurements was higher for cough epochs per hour compared to coughs per hour, suggesting that cough epochs might be a more consistent measure.
Limits of Nocturnal Cough Measures
In a prospective observational study, repeated-measure reliability was higher for cough epochs per hour than for coughs per hour, with intraclass correlation coefficients of 0.75 and 0.49, respectively. In children with stable CF, cough counts in the first night did not correlate significantly with counts in the second night. These findings suggest that repeatability can vary by measurement and night, so a single nocturnal cough measure warrants caution.
Adult CF and PCD Cough Frequency
An exploratory study compared inflammation and cough in children and adults with primary ciliary dyskinesia (PCD), cystic fibrosis, and healthy individuals. It reported a higher baseline cough frequency in adults with CF than in adults with PCD: 3.4 coughs per hour versus 0.69. This is an adult comparison from one exploratory study and does not establish a difference in children.
The Implications for Diagnosis and Treatment
This study offers a fresh perspective on how we understand and manage cough in CF and PCD. By demonstrating that nighttime cough patterns are linked to disease severity, it opens the door for more objective and personalized approaches to treatment. Monitoring nighttime cough frequency could potentially serve as a valuable endpoint in clinical trials, helping researchers to assess the effectiveness of new therapies. The use of cough epochs per hour, rather than just counting individual coughs, may provide a more reliable and consistent measure for tracking changes in cough patterns. Further research is needed to fully explore the potential of cough monitoring as a tool for improving the lives of individuals with CF and PCD.
Shared Respiratory Symptoms, Open Questions
A 2025 article describes chronic productive cough as the cardinal symptom of bronchiectasis and says it characterizes both CF and PCD. It also lists sputum production, dyspnea, fatigue, and occasional hemoptysis as respiratory symptoms. A 2018 nocturnal cough study stated that it aimed to test whether cough relates to disease-severity parameters and whether cough frequency differs between CF and PCD; the supplied description does not report its results.
Improving Prognosis and Studying Nighttime Cough
A 2023 Pediatrics article reports that treatment, prognosis, and quality of life for people with CF have improved steadily since the disease’s initial description, most dramatically in the past decade. It reports median predicted survival of 53 years in 2021, compared with 17 years in 1970. A MyStum article presents a recent study of nighttime cough in CF and PCD as a source of insights that could lead to better treatments, though the supplied description gives no specific study findings.
Treatment Impact Through Patient Reports
A June 2026 report says elexacaftor/tezacaftor/ivacaftor (ETI) has demonstrated significant improvements in lung function, body mass index, symptom control, and health-related quality of life in people with CF. A Vitaccess case study describes the Vitaccess Real platform powering a longitudinal study of patient-reported and caregiver-reported outcomes to evaluate treatment’s real-world impact. These reports show how treatment effects and patient and caregiver experiences can be represented in real-world research.